



Supplementary figures and legends

Figure S1



Supplementary figure 1: FAP expression in fibroblast cell lines. Western blot analysis shows that in each human fibroblast line (FEF3, NHLF and WI38) stimulated under a specific set of conditions (TGF-B, condition medium (CM) from TE4, or CM from the OE19; esophageal adenocarcinoma cell line) there was over-expression of FAP compared with controls, in a time-dependent manner.

Figure S2



Supplementary figure 2: Schematic of NIR-PIT methodology for CAF-targeting. (A) The IRDye700DX is conjugated to the FAP antibody. NIR-PIT is performed with NIR light measured using an optical power meter. (B) The *in vivo* protocol of NIR-PIT therapy for CAF-rich ESCC (TE4) tumors. NIR-PIT destroys intratumoral CAFs, resulting in tumor reduction.